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“Could this be genital Graft-versus-Host Disease?” 
The first patient about her genital signs and symptoms. 
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For my grandchildren: It is never too late to learn! 
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ABSTRACT 
 
BACKGROUND. Chronic graft-versus-host disease (cGvHD) is the major cause of 
morbidity after allogeneic hematopoietic stem cell transplantation (alloSCT), 
and contributes to non-relapse mortality. Caused by donor cells, cGvHD is a 
multi-organ syndrome involving tissue inflammation and fibrosis.  
AIMS. To describe female genital cGvHD; its symptoms, signs, prevalence, 
incidence, severity, relationship to androgen levels, and long-term outcome.  
STUDIES AND PARTICIPATING WOMEN. Study I: A cross-sectional, population-
based study (n=42), median 80 (13-148) months after alloSCT. Study II. A 
cohort study (n=65), 55 (3-194) months after alloSCT, controls (n=140).  
Study III, n=41, ≤36 months post alloSCT. Study IV, n=38, 174 (120-232) 
months post alloSCT. 
RESULTS. Study I: Cross-sectional. Prevalence of genital cGvHD was 52%. 
Symptoms, signs: dryness, smarting pain, dyspareunia; vaginal stenosis (n=9).  
Study II: Androgens and cGvHD. Corticosteroids and cGvHD were associated 
with low androgens.  
Study III: Prospective study. Cumulative incidence of genital cGvHD 66%, 
extra-genital cGvHD 76%, at 3 years. Early diagnostic signs: lichen planus-like 
signs, and synechiae, with no symptoms in 30 %. Vaginal total stenoses (n=2). 
Genital cGvHD could vary over time.   
Study IV: Follow-up study on women from Study 1 (n=38). Genital cGvHD 
prevalence 58%, no longer showing genital cGvHD (n=3), newly developed 
genital cGvHD (n=2). Prevalence and grade of cGvHD similar to Study I.  
CONCLUSIONS. Female genital mucosa is a major target for cGvHD. The 
incidence of genital cGvHD is high, and the prevalence does not decrease over 
time. Fibrotic signs may not disappear. However, treatment may alleviate 
symptoms and signs. Independent of symptoms, early gynecologic surveillance 
is important. Close contact between gynecologist and hematologist, permitting 
early diagnosis and local and/or systemic treatment may diminish the risk of 
developing severe fibrosis. Chronic GvHD, especially in combination with 
glucocorticoid treatment, is associated with low androgens and may contribute 
to deteriorated quality of life and sexual health.  
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SAMMANFATTNING PÅ SVENSKA 
 
INLEDNING: Allogen (från en annan människa) hematopoietisk (blodbildande) 
stamcellstransplantation (alloSCT) kan idag bota människor med maligna 
blodsjukdomar, tex leukemier. Det nya blodets T-lymfocyter angriper eventuella 
kvarvarande leukemiceller, Graft-versus-Leukemia-effekten, och bidrar till bot. 
Dessa T-lymfocyter kan även angripa patientens friska celler, Graft-versus-Host 
Disease (GvHD). Kronisk GvHD (cGvHD) är den vanligaste orsaken till  
sjuklighet och bidrar till död utan återfall efter alloSCT och inbegriper en 
inflammatorisk, fibrotiserande process som kan drabba alla organ men fr.a. 
slemhinnor i mun, ögon och genitalia. Kvinnors genitala cGvHD har länge varit 
underdiagnostiserad och otillräckligt behandlad.  
FRÅGESTÄLLNINGAR: Vår övergripande avsikt var en kartläggning av 
kvinnors genital cGvHD. Prevalens, incidens och samband med annan cGvHD? 
När och hur debuterar genital cGvHD? Med vilka tecken och symptom, då och 
senare? Kan tidig behandling minska risken för irreversibla skador, t ex 
vaginalstenos? Är cGvHD relaterad till sänkta androgener? Kan cGvHD läka ut? 
Påverkas sexualfunktion och livskvalitet? Kan histopatologi bidraga till 
diagnostiken? 
PATIENTER: Alla studier var populationsbaserade, Västra Götalandsregionen. 
Studie I var en cross-sectional studie av 42 kvinnor, 80 (13-148) mån efter 
alloSCT aug. 1996 - nov 2005. Studie II omfattade 65 kvinnor med alloSCT 1996 
- 2012. Kontroller var kvinnor i) efter autolog SCT (får tillbaka egna stamceller) 
1996 - 2010 (n=20), ii) med kortisonbehandling utan SCT (n=26), iii) friska 
åldersmatchade (n=94). Studie III var prospektiv, inkluderande kvinnor med 
alloSCT Sept 2005 - Febr 2010 (n=41), som följdes under 3 år. Studie IV är en 
långtidsuppföljning av alla överlevande kvinnor från Studie I (n=38).  
METODER: Egenrapportering av genitala besvär i strukturerade formulär om 
gynekologisk historia, annan ohälsa, medicinering; Female Sexual Distress Scale 
och Beck Depression Inventory i Studie I, III o IV. Gynekologiska och 
allmänmedicinska undersökningar med strukturerad dokumentation i Studie I, III 
och IV, stansbiopsier i studie I, cytologprov och HPV-test i Studie IV; 
oftalmologisk och klinisk gradering av extra-genital cGvHD i Studie IV. 
Blodanalyser i Studie II avseende bl.a. androgena hormoner. Stansbiopsierna i 
Studie I bedömdes av två patologer. All cGvHD kategoriserades enligt 
internationella riktlinjer (National Institutes of Health (NIH) 2005 och 2014). 
Lokalbehandling i Studie III, inleddes med lokalt östrogen och därefter enligt 
strukturerat schema med clobetasol och tacrolimus. I Studie I ställdes diagnosen 
genital cGvHD först efter 6 veckors lokal östrogenbehandling.  
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RESULTAT: Studie I: Prevalensen av genital cGvHD var 52% (n=22); 12 
kvinnor hade svår genital cGvHD (9 stenoser), och 5 isolerad genital cGvHD. 
Torrhet, sveda, smärta och dyspareuni vanligare vid genital cGvHD än utan 
(p<0.05). Tretton (31%) kvinnor hade både genital cGvHD och steroidkrävande 
extragenital cGvHD. Vi fann inget samband mellan histopatologi och klinisk 
diagnos. Alla kvinnor var i menopaus, naturlig eller prematur. Studie II: Låga 
serumandrogener var associerade med kortisonbehandling och cGvHD. Studie 
III: Första diagnostiska tecken var lichen planus-liknande förändringar och 
synekier - dock utan symptom i 30%. Kumulativ incidens 3 år efter alloSCT av 
extra-genital cGvHD 76% och genital 66%, flertalet med debut inom 1 år post 
alloSCT; senaste debut efter 30 mån. Fem kvinnor utvecklade partiell vaginal-
stenos varav 2 även total stenos . Genital GvHD uppträdde intermittent. Lokal 
östrogenbehandling gavs till alla, systemisk hormonsubstitution till dem i för tidig 
menopaus, vilket drabbade alla som inte redan var i naturlig menopaus. Lokal 
immunosuppressiv behandling gavs till 13 kvinnor. Studie IV: prevalens av 
genital cGvHD 58%. Av 22 kvinnor med genital cGvHD i Studie I var 3 döda och 
3 hade inte längre genital cGvHD. Två kvinnor hade utvecklat genital cGvHD 5-
17 år efter alloSCT. Ingen skillnad sågs mellan Studie I och IV avseende prevalens 
eller svårighetsgrad av genital och extra-genital cGvHD på gruppnivå, men 
enskilda kvinnors svårighetsgrad av genital cGvHD kunde variera.   
SLUTSATSER: Genital cGvHD är mycket vanlig efter alloSCT. Oberoende av 
symtom är tidig och systematisk gynekologisk kontroll viktig. Nära kontakt med 
hematolog, tidig diagnos och lokal behandling kan minska risken för utveckling 
av allvarlig fibros. Livslång kontroll är nödvändig på grund av ökad risk för 
epiteliala cancrar som t.ex. cervixcancer. Kronisk GvHD, särskilt vid samtidig 
kortisonbehandling, är associerad med låga androgener och kan bidra till 
försämrad livskvalitet och sexuell hälsa. 
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PREFACE 
 
My research on genital chronic Graft-versus-Host Disease (GvHD) started on 
the 25th of May 2000 – without my knowledge. That day at an antenatal clinic, 
the midwives had given an appointment to a woman, who recently had 
undergone an allogeneic stem cell transplantation. She had genital problems and 
was a fellow-worker. Her problems were caused by premature menopause, and 
easy to help with local and systemic hormone replacement therapy. A few 
months later new problems appeared. “Could this be genital Graft-versus-Host 
Disease?” the woman asked me. And that was the real beginning!  
 
The hematologists started referring to me allografted women with genital 
complaints. By the summer of 2005 I had seen 10 women with genital chronic 
GvHD (cGvHD). I asked myself, what I should do with all this accumulating 
knowledge. I knew that other gynecologists knew very little about genital 
cGvHD. At that time, the hematologist Mats Brune called me. “There is a 
comprehensive new textbook on cGvHD, with only 20 lines on genital cGvHD. 
Shall we do a study of genital cGvHD?” There was only one answer to that!     
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1 BACKGROUND 
1.1 Allogeneic Hematopoietic Stem Cell Transplantation 
1.1.1 Introduction 
Allogeneic hematopoietic stem cell transplantation (alloSCT) is an established 
treatment for malignant (e.g. acute and chronic leukemias) and also some non-
malignant (e.g. aplastic anemia) diseases. The curative potential of a 
conventional alloSCT is due to a combination of the myeloablative conditioning 
(MAC) i.e. high-dose chemotherapy and/or irradiation, and an immunological 
graft-versus-leukemia (GvL-) effect, exerted by the donor´s immunocompetent 
cells, mainly T lymphocytes. The GvL effect was first illustrated by Mary 
Horowitz 1990 in a registry study demonstrating an increased relapse rate if the 
donor was an identical twin rather than a matched sibling donor (1).  
In Sweden, alloSCT is routinely performed at 6 university hospitals and, as in 
most other countries, the number of allografted patients has increased. Also, the 
indications for alloSCT have widened, from acute and chronic leukemias in 
young patients to an array of malignant and sometimes non-malignant diseases 
in patients up to the age of 70 years.  
 
1.1.2 Toxicity  
Unfortunately, the benefits of allografting either from a Human Leukocyte 
Antigen (HLA-) matched sibling donor (MSD) or from a voluntary HLA-
matched unrelated donor (MUD), are partially offset by procedure-related 
toxicity, and non-relapse mortality (NRM), both of these problems increasing 
with patient´s age. Actually, accumulated NRM in Acute Myeloid Leukemia 
(AML) patients is still 15-20%, also in younger patients (2). Indeed, one report 
from a contemporary study accounted for 34% NRM after MUD transplants in 
elderly patients (3). 
 
1.1.3 Conditioning, myeloablative or reduced 
There is a sustained rise in number of alloSCT which is mainly attributable to a 
rapid increase of reduced intensity conditioning transplants (RICT). The 
conceptual basis of RICT is to deliver a less toxic conditioning, and 
consequently benefit from the GvL effect. The intuitively attractive notion of 
reduced toxicity and an active GvL-effect has encouraged clinicians to perform 
RICTs in elderly and/or medically infirm patients. However, in a randomized 
trial, the reduced toxicity with RICT may come with an increased risk of 
relapse, outweighing the lower NRM(4).  
 
1.2 Autologous SCT   
Autologous SCT (autoSCT) relies on the effect of the heavy conditioning only. 
The stem cells have been collected from the patient, and kept frozen. After the 
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conditioning, the stem cells are infused and restore the patient´s bone marrow 
function within 10-15 days. Obviously, there is no GvHD or any GvL effect 
following autoSCT.  
 
1.3 Complications after alloSCT 
1.3.1 Relapse  
Although not formally a complication after alloSCT, relapse is by far the worst 
and most ominous event after alloSCT. The risk of relapse is dependent on the 
original disease – e.g. transplant of an AML patient with multiple chromosomal 
aberrations bears a high risk of early relapse, whereas an allografted patient with 
intermediate risk AML showing no measurable residual disease (MRD) has a 
much better prognosis (5).  
 
1.3.2 Infections  
After alloSCT, tissue damage and the eradication of neutrophils leave the patient 
highly vulnerable to infections. In particular, early Gram-negative bacterial 
infections are a great danger. Therefore, prophylactic antibiotics are used to 
prevent fatal infections. Following engraftment (normally occurring 12-15 days 
post-transplant) other agents including fungi and opportunistic viruses constitute 
a second wave of infectious threats. Fungal infections or activation of 
cytomegalovirus (CMV) are common problems. The allografted patient has an 
increased risk of infection for many years to come. Indeed, herpes zoster or 
human papilloma viruses (HPV) may flare-up years after transplant. In all, early 
or late infections account for one third of non-relapse mortality. Ongoing GvHD 
and ensuing immunosuppressive treatment markedly increase the risk of 
opportunistic infections (6).  
A complete vaccination program is mandatory for all patients after alloSCT(7).  
 
1.3.3 Other complications after alloSCT  
Numerous late effects of alloSCT may strike the allografted patient. In addition 
to acute or chronic GvHD (see below) and the side effects of its treatment 
(systemic corticoid steroids), renal and pulmonary insufficiency, infections, 
anxiety, fatigue, and many more infirmities often reduce the patient´s quality-of-
life (8).  
 
1.4 Graft-versus-Host Disease  
1.4.1 Introduction  
In 1966, R. Billingham defined a syndrome presented in an article called “The 
biology of graft-versus-host reactions”(9). This is a syndrome in which donor 
lymphocytes recognize and attack host tissues. Prophylaxis of acute GvHD 
consists of immunosuppressive drugs: ciclosporin or tacrolimus, and 
methotrexate or mycophenolate mofetil. Pre-transplant infusion of polyclonal 
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antibodies, anti-thymocyte globulin (ATG), decreases the risk of late onset 
(chronic) GvHD (see below)(10). 
 
1.4.2 Acute GvHD  
Acute GvHD (aGvHD) is a sometimes dramatic demonstration of donor cells´ 
immunological capacity(11). Typically, donor lymphocytes attack skin, liver 
and gut within the first 4 months post-transplant. Primary treatment includes 
local immunosuppressive ointments and systemic high-dose corticosteroids. 
Response rate is 75%, but opportunistic infections (CMV, Epstein-Barr Virus, 
aspergillosis) are common. If there is no treatment response, the patient 
deteriorates, and mortality is high, usually due to intestinal acute GvHD and/or 
infection.  
 
1.4.3.1 Chronic GvHD  
Chronic GvHD “involves multiple, distinct interactions among alloreactive and 
dysregulated T and B cells and innate immune populations, including 
macrophages, dendritic cells, and neutrophils, that culminate in the initiation and 
propagation of profibrotic pathways” (12). Most common sites of cGvHD are 
mucous membranes in mouth, conjunctivae, and female genitals. However, 
almost any organ or tissue may be affected, e.g. skin (65-80%), mouth (48-
72%), genitals (30-70%), eyes (18-47%), and liver (40-73%) (8). Fibrosis 
succeeding the inflammatory process may lead to scleroderma, bronchiolitis or 
vaginal stenosis. Thus, cGvHD may resemble any autoimmune disease 
including systemic sclerosis, Sjögren´s syndrome, lichen planus and 
bronchiolitis obliterans. For a review of cGvHD, its symptoms, signs and 
categorization, see Lee S J (13).  
 
Acute and chronic GvHD may appear in parallel (“overlap syndrome”) early 
after transplant. However, that is a rare scenario, and typically cGvHD comes 
with dry mouth and eyes, sometimes skin rash, 3-6 months after transplant. Risk 
factors are HLA mismatch, female donor to male patient, unrelated donor and 
transplants using peripheral blood stem cells (PBSC) (14). The incidence of 
cGvHD has increased over the last 20 years in spite of better HLA matching 
between unrelated donor and patient. The high amount of lymphocytes in the 
PBSC product is considered to be the factor behind the increased rate of 
cGvHD, which is the dominant problem in relapse-free patients after alloSCT.  
Interestingly, mild cGvHD is associated with lower risk of relapse compared 
with no cGvHD, suggesting that the immunological mechanism(s) operative in 
cGvHD and GvL are identical. However, higher grades of cGvHD, and the 
systemic immunosuppression used, render risk of infections, impaired general 
health and wellbeing, and ensuing risk of mortality.  
Eva Smith Knutsson 
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1.4.3.2 Treatment of cGvHD 
Management of mild cGvHD includes topical corticosteroids and moisturizing 
ointments, whereas in moderate or severe cGvHD systemic corticosteroids are 
the mainstay of treatment. Chronic GvHD and its treatment increase the risk of 
opportunistic infections, in addition to cGvHD related fatigue, reduced quality-
of-life, diabetes, alopecia and secondary cancers (15).  
There are international guidelines for preventing and treating infectious 
complications after alloSCT (6, 8). 
 
1.5 Genital chronic GvHD 
1.5.1 Early reports 
Genital cGvHD was first described by Stephen Corson et al. in Obstetrics & 
Gynecology in a report on five patients, four of whom developed vaginal 
stenosis (16). The treatment was local estrogen and surgery followed by use of 
vaginal dilators and systemic immunosuppression. Similar reports of genital 
cGvHD, describing vaginal stenosis with or without hematokolpos or 
hematometra, were published from 1999 onwards. Lönnqvist & Brune described 
two cases with dyspareunia and bloody discharge making coitus impossible. 
Signs and symptoms healed after 2 weeks of treatment with local hydrocortisone 
ointment (17).  
 
1.5.2 Subsequent reports 
In 2003, Spinelli et al. published a study of 213 women who had been referred 
because of gynecological symptoms after alloSCT. Retrospective analyses of the 
medicals records indicated that 53 women had genital cGvHD (18). The authors 
proposed the first grading of genital cGvHD as minimal, moderate and severe. 
Vaginal adhesions or complete vaginal closure were considered diagnostic of 
severe genital cGvHD.  
 
In the same year (2003), Spiryda et al. published “Graft-versus-Host Disease of 
the Vulva and/or Vagina: Diagnosis and Treatment” (19). Eleven cases of 
vaginal scarring were described. They reported good effect of topical ciclosporin 
only, or combined with surgery in severe cases. All women were on hormone 
replacement therapy (HRT) and six needed also topical estrogen due to vulvar 
and/or vaginal atrophy. Two women were treated for persistent dysplasia.  
 
Zantomio et al. (2006) described a prospective surveillance program of female 
patients with genital cGvHD who survived at least 6 months post alloSCT (20). 
They concluded that genital cGvHD is common, and that early detection and 
topical immunosuppression, together with dilator use, appear to be effective at 
preventing progression. They stressed the importance of pre-transplant counsel, 
early hormone replacement, regular post-transplant gynecological examinations, 
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and the need for a close cooperation between hematologists and gynecologists.  
 
In 2007, Stratton et al. (21) published data on 29 women and confirmed earlier 
findings presented by Zantomio . The authors showed that a combination of 
topical estrogen and a potent glucocorticoid, and vaginal dilator and estrogen 
ring (if vaginal scarring) was efficient treatment of genital cGvHD. An 
important observation was that women with ovarian function or HRT healed 
more rapidly than those who were hypoestrogenic. All women with genital 
cGvHD also had extra-genital cGvHD. Stratton modified the scoring of Spinelli 
and presented a list of “Severity scoring for vulvo-vaginal GvHD” with 
minimal, moderate and severe grades (or I-III). Twenty-eight women debuted 
with vulvar cGvHD and 13 of these patients either had or developed vaginal 
cGvHD. The authors concluded that vulvar cGvHD always precedes vaginal 
cGvHD. In accordance with previous findings, they noted that systemic 
immunosuppressive treatment of extra-genital cGvHD does not hinder 
development of genital cGvHD.  
 
Hirsch et al. (22) suggested that local mucosal paleness actually is an early 
clinical manifestation, grade I, of genital cGvHD. They used the principles of 
the grading system proposed by Stratton, and concluded that “systematic, early 
and regular specialized gynecologic consultation should be performed in every 
alloSCT recipient”. 
 
For a summery see Table 1. 
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Table 1. Previous papers on genital cGvHD. 
 
Article Recruit n Design Incidence Treatment Comments 
Spiryda 
2003 
Vaginal 
symptoms 
in spite of 
estrogen 
treatment 
11 Retro- 
spective 
 Topical 
estrogen, 
cyclosporine 
vag cream. 
Prednison 
cyclosporine. 
Description of 
vaginal cGvHD; local 
immunosuppressive 
therapy and surgery 
(7/11) and cervical 
dysplasia (2/11) 
Spinelli 
2003 
AlloSCT 
1980-99 
 
213 Retro- 
spective 
Cumulative 
incidence 
24.9% at 
8.9 years 
Topical 
estrogen, 
triamcinolone, 
clobetasol 
Own grading; no 
connection between 
parity or vaginal 
infection and GvHD; 
regards HRT as 
enough estrogen 
treatment of vulvo-
vaginal mucosa 
Zantomio 
2006 
AlloSCT 
1999-
2004 
61 Retro- 
spective 
Incidence 
35% at 1 
year, 49% 
at 2 years 
HRT. Topical 
estrogen, 
hydrocortisone, 
& cyclosporine 
Own severity 
grading similar to 
Spinelli´s 
Stratton 
2007 
Referred 
for genital 
symptoms 
or part of 
systemic 
evaluation 
33 Obser-
vational 
 Topical 
estrogen, 
topical 
clobetasol 
Modified Spinelli 
grading. Women 
with estrogen healed 
quicker than 
hypoestrogenic; 
vulvar cGvHD 
always preceded 
vaginal 
Hirsch 
2012 
With 
genital 
GvHD 
AlloSCT 
2000-10 
32 Retro- 
spective 
 Local estrogen 
HRT, 
local 
corticosteroid, 
systemic 
cyclosporine 
Modified Stratton 
grading; local 
paleness; 
emphasize the 
importance of long-
term follow-up after 
alloSCT and long-
term treatment 
cGvHD, chronic Graft-versus-Host Disease; alloSCT, allogeneic stem cell transplantation; HRT, 
hormone replacement therapy 
 
1.5.3 Clinical guidelines on the management of genital cGvHD 
Typically, early guidelines described the female genitals as organs with 
endocrine dysfunction after alloSCT, and with an elevated risk for cervical 
malignancy(23, 24). Vaginal cGvHD is mentioned as causing strictures and 
synechiae. 
From 2008, more attention is paid to the female genital cGvHD, and post-
transplant examination of the genitals is recommended, in symptomatic women 
(25, 26) or all women (27-29).  
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1.5.4 Treatment of genital cGvHD 
Corson recommended systemic prednisone and azathioprine as the treatment of 
genital cGvHD (16). In articles from 2003 and onwards, local 
immunosuppressive therapy is advised including topical use of clobetasol and/or 
ciclosporin or tacrolimus (18-21, 30). Most authors begin treatment with HRT 
and local estrogen to distinguish estrogen deficiency caused atrophia from 
genital cGvHD, and also because estrogen treated mucosa heals more rapidly on 
specific cGvHD therapy (21). If inadequate effect, systemic corticosteroids may 
be used (30). In vaginal cGvHD most authors propose the use of vaginal 
dilators, if coitus is not an option, both to keep the vaginal volume intact and to 
stretch the narrowing synechiae or circumferential vaginal bandings. 
 
1.5.5 Genital cGvHD and cervical dysplasia  
Savani et al. conducted a cross-sectional study of 35 patients at a minimum of 3 
years posttransplant (31). HPV related cervical dysplasia was significantly 
associated with cGvHD requiring prolonged systemic immunosuppressive 
therapy. Most of these 35 women had normal cervical smears prior to alloSCT. 
In 2013, Sri et al. published a case report showing a relationship between the use 
of local immunosuppressive agents and HPV reactivation and spread (32). Wang 
et al. (33) performed a clinical study of cervical dysplasia in long-term survivors 
after alloSCT in Norway, and found that all alloSCT survivors were at high risk 
for cervical cytological abnormalities. Rizzo et al. studied a multi-institutional 
cohort of 28 874 allogeneic transplant recipients with 189 solid malignancies 
(34). The development of cGvHD was associated with a 5-fold increase in risk 
of squamous cell cancers (SCC). 
 
1.6 Sexual function and depression after alloSCT 
Humphreys et al. published a 3-years longitudinal study on sexual function in 
women after alloSCT (35). Half of the patients had had no discussion of sexuality 
with their health care providers during the 3 years. Baseline or pre-transplant level 
of depression was significantly related to sexual function at year 3 after alloSCT. 
Patients who were not sexually active reported fewer sexual difficulties. Those 
who had had a discussion of transplant effects on sexuality with their health care 
providers reported significantly fewer sexual functioning problems. In this paper, 
no data on the prevalence of cGvHD was presented, nor was the putative effect of 
genital cGvHD on sexual life discussed.  
Li et al. in a review article stress the importance of screening for sexual 
dysfunction by asking about genital symptoms and performing genital 
examinations as part of the routine assessments after alloSCT (36). They noted 
the importance of physical necessary conditions for a functioning sexual life 
such as estrogen treatment of genital mucosa, treatment of genital cGvHD and 
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depression, regular medical review and elimination of polypharmacy to reduce 
sexual side effects.  
 
Noerskov et al. made a prospective study for 1 year after alloSCT and found a 
significant decline in overall sexual function in both men and women. Of the 
women, 60% reported at least 1 physical sexual problem 1 year after alloSCT 
(37). Lack of libido and physical or sexual problems were rated equally as 
reasons for absence of sexual activity. Low arousal was the only sexual function 
correlated with depression. Women with cGvHD reported more sexual problems 
than those with no cGvHD. The authors ask for future studies on how the 
inevitable decline in endogenous sexual hormones influences sexual function in 
both men and women. Information is essential to improved understanding of the 
mechanisms behind the development of sexual dysfunction. In addition, the 
authors stress the importance of having a dialogue with the patients about sexual 
function as an integral part of cancer care.  
 
Thygesen et al. published a review of the literature and summarized that some 
recovery of sexual activity and pleasure occurs during the first 2 years after 
transplantation (38). Yet, even 5-10 years after their cancer treatment survivors 
experienced more sexual dysfunction than controls. Typically, sexual 
dysfunctions were reported as lack of sexual interest, alterations in body image, 
vaginal dryness, vaginal tightness, fibrosis and painful intercourse. 
 
1.7 Androgen hormones in women after alloSCT 
Hovi et al. published an article where they had studied ovarian function and sex 
hormone production with special focus on androgens (39). Twenty-four young 
women (16-33 years of age) were followed up during 1.5–20 (mean 9) years 
after bone marrow transplantation (BMT). Subnormal testosterone levels were 
observed in 43% of BMT patients and subnormal dehydroepiandrosterone 
sulfate (DHEAS) levels in 34% of BMT patients, the latter being a constant 
finding during glucocorticoid therapy (GC) for cGvHD. Their question was 
whether the subnormal androgen levels are dependent on the result of 
dysfunctional ovaries or cGvHD with corticosteroid therapy, and secondary 
adrenal cortex insufficiency.  
 
Davison et al. studied androgen levels in relation to age, menopause and 
oophorectomy in healthy adult females. They found that serum androgen levels 
decrease from the early reproductive years following a slow steady decline with 
age, unrelated to menopause (40). 
 
Female genital Graft-versus-Host Disease 
 10 
1.8 Not yet studied? 
Our project was planned in 2005, the same year as the National Institutes of 
Health (NIH) consensus document on “criteria for clinical trials in chronic graft-
versus-host disease: I. Diagnosis and staging working group report” was 
published (41). There were no reports on population-based prevalence of genital 
cGvHD, no reports on prospective studies or long-term follow-up. No one had 
addressed the question raised by Hovi (39) regarding the putative effect of 
cGvHD on androgen levels in women. 
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2 AIMS 
The overall aim of this thesis was to study genital cGvHD with respect to its 
prevalence, incidence, symptomatology, long-term prognosis and relationship to 
androgen hormone levels. 
 
THE SPECIFIC AIMS WERE:   
 
PAPER I  
To determine the prevalence, signs, symptoms and histopathological features of 
genital cGvHD in a cross-sectional, population-based cohort of allografted 
women.  
 
Paper II 
To try and establish any impact of alloSCT and cGvHD, with or without 
systemic glucocorticoids, on androgen hormones. Controls were (i) women in 
remission after autologous transplantation, (ii) women with gluco-corticoid 
treatment for inflammatory diseases, (iii) healthy age-matched women. 
 
Paper III 
To follow a population-based cohort of allografted women to find out how, 
when and where genital cGvHD debuts, and to establish its cumulative 
incidence, and its relationship to extra-genital cGvHD and to depression and 
sex-related personal distress, and by early diagnosis and treatment try to hinder 
the development of more severe genital cGvHD. 
 
Paper IV  
To study the long-term outcome with respect to genital, ocular and other cGvHD 
in surviving women from the first study (Paper I).  
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3 PATIENTS AND METHODS 
3.1 Patients 
All patients were females living in the Region Västra Götaland (VGR), Sweden, 
an area with approximately 1.5 million inhabitants. Patients and controls signed 
informed consent. Ethical approvals for all studies were obtained from the 
Regional Ethical Review Board, Gothenburg.  
Paper I. Eighty-six women were allografted from August 1996 to November 
2005. Fifty surviving women in complete remission were identified and of these, 
2 women declined participation, 3 were not invited due to mental disability, and 
3 were excluded for other reasons. Thus, 42 women were enrolled (42).  
Paper II. A total of 166 women from VGR underwent alloSCT at Sahlgrenska 
University Hospital from January 1996 to September 2012. Seventy-six 
surviving women in complete remission (CR) were identified living in Borås, 
Trollhättan and Gothenburg. Five were not invited to participate, owing to 
mental disability (n=1), insufficient Swedish language proficiency (n=3), and 
missing data (n=1). Six women declined participation. Thus, 65 women were 
enrolled. Forty-five of the 65 allografted women in Study II were also included 
in our other studies: 24 women took part in Study I and of these, 22 were also 
included in Study IV. Another 21 women were included in Study III (43).  
Paper III. Fifty-two women scheduled for alloSCT from September 2005 to 
February 2010 were eligible. Four women declined to participate, 5 died or 
relapsed early, and 2 participated in study I. Thus 41 (79%) women were 
included at the pre-alloSCT gynecologic examination (n=22) or after transplant 
(n=19) (44).  
Paper IV. Almost 7 years after Study I, 38 of the 42 participating women were 
still alive without relapse, and all of these accepted to participate in a long-term 
follow-up study. Four women had died: causes of death were cGvHD, 
pancreatic cancer, leukemia and amyotrophic lateral sclerosis (Manuscript). 
 
For a summery see Table 2. 
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Table 2. Overview of the studies presented in this thesis. 
 
Study 
 
AlloSCT 
(n) 
Incl. 
Period 
In 
study 
(n) 
Design Aims 
Follow-up 
months 
post 
alloSCT 
I 84 
1996 Aug 
2005 Nov 
42 
Cross 
sectional 
Prevalence 
80 
(13–148) 
II 166 
1996 Jan 
2012 Sep 
65 
Cross 
sectional 
Androgens & 
cGvHD 
55 
(3–194) 
III 52 
2005 Sep 
2010 Feb 
41 Prospective 
Cumulative 
incidence 
36 
IV 84 
1996 Aug 
2005 Nov 
38 
Cross 
sectional 
Late prevalence 
174 
(120–232) 
alloSCT, allogeneic stem cell transplantation; 
 
3.1.2 Controls 
In Paper II, three groups of women served as controls:  
1. Twenty women in complete, or partial remission (PR) with no ongoing 
chemotherapy after autologous SCT. Diagnoses were myeloma (n=7), 
multiple sclerosis, (n=1), lymphomas (n=12).  
2. Twenty-six women without previous SCT but with ongoing 
glucocorticoid (GC) therapy (GC group). Indications for GC therapy were 
rheumatic disease without biological treatment (n=8), lung disease (n=6), 
or benign hematological disease: idiopathic thrombocytopenic purpura, 
autoimmune hemolysis (n=12).  
3. Ninety-four healthy age-matched women with intact ovaries. Eighty-one 
of these were health care employees.  
 
3.2 Methods 
3.2.1 Clinical scoring according to NIH 2005  
The traditional way of classifying cGvHD was to use the 3 terms none, limited 
or extensive. However, the basis for this division was imperfect and there was a 
lack of precise definition of the terms used.  
In 2005, NIH published a clinical scoring system (0-3) for the evaluation of 
cGvHD involvement of individual organs and sites (NIH 2005) (41). Diagnosis 
of cGvHD should be made after assessment of signs and symptoms, laboratory 
tests, and (rarely) histopathological examination. The document defined criteria 
for scorings of organs including genitals, eyes, mouth, skin, nails, body hair, 
lungs, GI tract, liver, muscles, fascia, and joints. 
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As an example, scoring of ocular cGvHD was based on symptoms and signs.  
Score 0: No symptoms. 
Score 1: Mild dry eye symptoms i.e. eyedrops ≤3 times daily or 
asymptomatic signs of keratoconjunctivitis sicca (KCS). 
Score 2: Moderate dry eye symptoms partially affecting activities of 
daily living (ADL) (eye drops >3 times daily or punctal plugs, but 
without vision impairment  
Score 3: Severe dry eye symptoms significantly affecting ADL, or 
unable to work or loss of vision.  
For the clinical scoring of genital cGvHD, signs were categorized as 
mild, moderate or advanced; symptoms as minimal, mild, or severe. In 
practice, this symptombased scoring system implied that a woman with a 
complete vaginal stenosis, but with no symptoms, scored 0 for genital cGvHD 
(Table 3). Clinical scoring according to NIH 2005 was performed in Study I and 
III. 
 
3.2.2 Clinical scoring of cGvHD according to NIH 2014 
An update of the NIH consensus document was published 2015 (NIH 2014) with 
modifications of diagnostic criteria and scoring system inter alia for eyes and 
female genitals (45). The traditional Schirmer’s test was withdrawn as a 
diagnostic tool, and KCS confirmed by an ophthalmologist in an asymptomatic 
patient (score 0) has been incorporated. Ocular score 2 was defined as new 
vision impairment due to KCS. Clinical score 3 was unchanged. 
In contrast to NIH 2005, genital clinical scoring of cGvHD in the NIH 2014 
classification focused on signs (see Table 3). NIH 2014 emphasizes that there 
are no symptoms specific for genital cGvHD. Clinical scoring according to NIH 
2014 was performed in Study IV, and retrospectively in surviving women in 
Study I. The data in Study I were revised, on the basis of data on gynecological 
status, medical records and photographic evidence. Minor corrections were 
made, leading to the placement of 2 more women in the group with no extra-
genital cGvHD. 
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Table 3. Genital clinical scoring according to NIH 2005 and 2014  
Adapted from Filipovich (2004) & Jagasia (2015) 
 
Genital clinical 
score 
Score 0 Score 1 Score 2 Score 3 
NIH 2005 No symptoms 
(independent of 
sign) 
Symptomatic 
with mild signs 
on exam and no 
effect on coitus 
and minimal 
discomfort with 
gynecologic 
exam 
 
Symptomatic 
with moderate 
signs on exam 
and with mild 
dyspareunia or 
discomfort with 
gynecologic 
exam 
Symptomatic 
with advanced 
signs and severe 
pain with coitus 
or inability to 
insert vaginal 
speculum 
NIH 2014 No signs Mild signs and 
may have 
symptoms with 
discomfort on 
exam 
Moderate signs 
and may have 
symptoms with 
discomfort on 
exam 
Severe signs with 
or without 
symptoms 
 
 
3.2.3 Global scoring of cGvHD 
The global scoring system is based on the clinical scoring of affected organs. 
NIH 2005 proposed an assessment of severity (mild, moderate, or severe) of 
cGvHD by combining the number of organs involved, and clinical scoring of 
each affected organ. This global scoring system aimed to reflect the total clinical 
impact of cGvHD on the patient’s functional status and remained by and large 
unchanged in the NIH 2014 document. 
• Mild global score is the presence of 1-2 organs with clinical score 1.  
• Moderate global score is the presence of  
- at least 1 organ or site with clinical score 2. 
- or 3 or more organs with clinical score1 in all affected organs 
- or lung score1 
• Severe global score is the involvement of clinical score 3 in any organ or 
a lung score 2 or greater. 
Global scoring was applied in Study I and Study IV. The global severity of each 
woman´s cGvHD was categorized by combining genital and extra-genital 
clinical scores. 
 
3.3. Other clinical cGvHD (not genital, not ocular) 
All allografted women were followed as outpatients at the BMT1 clinic. In 
Studies I and III clinical (not genital, not ocular) cGvHD data were retrieved 
                                                     
1 Bone Marrow Transplantation Clinic. Section of Hematology. Sahlgrenska University 
Hospital, Gothenburg. 
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from medical records and registered by study hematologists (Y.B. and M.B.). 
For Study IV, each patient was examined with respect to genital, ocular and 
other cGvHD on the same day.  
 
3.4 Ocular cGvHD 
The ophthalmological examinations in Study I and Study III were sporadic and 
based on symptomatology. However, in Study IV all women were seen by an 
experienced ophthalmologist. Oral anamnesis included eye history, vision 
problems, cataract operation and use of lubricating eye drops and corticosteroid 
eye drops. Vision, Schirmer´s test, ocular pressure, ophthalmoscopy and corneal 
microscopy of eyelids, conjunctiva and cornea were done. Break up time and 
chemosis were studied. All clinical signs were noted including those of 
inflammation, punctual erosions, papillary and follicular reaction. In NIH 2005 
only distinctive signs were reported: new onset dry, gritty, or painful eyes, 
photophobia, cicatricial conjunctivitis, KCS and confluent areas of punctate 
keratopathy (41). In NIH 2014 signs as “New ocular sicca documented by low 
Schirmer´s test with a mean value of 5 mm at 5 minutes” or “new onset of KCS 
by slit lamp exam with Schirmer’s test 6 to 10 mm” are considered diagnostic 
for ocular cGvHD - if the signs are not due to other causes (45).  
 
3.5 Genital cGvHD 
Diagnosis of genital cGvHD according to both NIH 2005 and NIH 2014 requires 
at least 1 diagnostic sign or 1 distinctive cGvHD sign together with a diagnostic 
tissue biopsy or confirmed cGvHD in other organ(s) (41, 45). 
The definitions of genital diagnostic signs in NIH 2005 were lichen planus-like 
features, and/or vaginal scarring. Erosions, fissures and ulcers were considered 
distinctive signs.  
In NIH 2014 the distinctive signs remained the same.  
 Diagnostic mild signs were erythema on vulvar mucosal surfaces, 
vulvar lichen-planus or vulvar lichen-sclerosus-like features.  
 Diagnostic moderate signs included erosive inflammatory changes of the 
vulvar mucosa or fissures in vulvar folds.  
 Diagnostic severe signs included labial fusion, labial agglutination, vulvar 
synechia, clitoral hood agglutination, fibrinous vaginal adhesions, 
circumferential fibrous vaginal banding (partial stenosis – author´s 
comment), vaginal shortening or synechiae, dense sclerotic changes, and 
complete vaginal stenosis. 
Gynecologic examinations included detailed structured documentation of 
vulvovaginal signs, and often photo-documentation of the vulva. 
Examinations were done by one or both of the assigned gynecologists (A-KB 
and/or ESK). In Study I all women with atrophic mucous membranes were 
treated with local estrogen for a minimum of 6 weeks before the diagnosis of 
genital cGvHD was made. The reason was to avoid interpretation of genital 
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atrophia as genital cGvHD. All women were seen at least twice. For Study III, 
each woman was examined before alloSCT, and at +3, 6, 9, 12, 18, 24, 30 and 
36 months after alloSCT. In Study IV the women were seen once by one 
gynecologist (ESK). 
In Study I and Study III, the diagnosis of genital cGvHD was based solely on 
genital signs, according to the NIH 2005 consensus criteria. The NIH 2014 
criteriae were used in Study IV. A fibrotic sign i.e. a sore vaginal string was 
considered a diagnostic sign in Study III and Study IV (19, 21, 42). We also 
considered red and white spots occurring together, giving the mucous membrane 
a mottled appearance, a distinctive sign (22, 42). 
At each study visit the woman completed or updated a comprehensive 
questionnaire on her general gynecological and medical history, gynecological 
symptoms, local and systemic medication. Symptoms were self-reported as 0, 
never; 1, seldom; 2, sometimes; 3, often; or 4, always. Symptoms asked for 
included itching, smarting pain, swelling, pain with and without touching, 
blisters, fissures/wounds, dryness, discharge, vaginal and/or vulvar constriction 
and dyspareunia. Cervical smear sampling was part of the protocol in Study IV 
only, but was performed according to the Swedish cervical cancer screening 
program and on clinical signs or symptoms in Studies I and III. HPV-test 
became more of a clinical routine during the project and was part of the protocol 
in Study IV.  
 
3.5.1 Treatment of genital cGvHD 
AlloSCT is known to affect the ovaries, causing premature menopause (28, 46). 
HRT was prescribed to all women in premature menopause. Local estrogen 
treatment was recommended for women with clinically atrophic mucous 
membranes. In Study I, the diagnosis of genital cGvHD was not made until after 
6 weeks of local estrogen treatment. In Study III, first treatment of genital 
cGvHD was local estrogen therapy. Depending on signs, symptoms and 
histopathological findings, local immunosuppressive therapy was combined with 
continued local estrogen. Local ointments, clobetasol (0.05%) and/or tacrolimus 
(0.1-0.03%) were prescribed as first-line immunosuppressive therapy for genital 
cGvHD, and a dilator was recommended for vaginal cGvHD. We followed a 
structured treatment schedule (see Table 2, Paper III), based on the current 
Swedish recommendations for treatment of genital lichen sclerosis, published 
reports on tacrolimus use for atopic dermatitis and cutaneous cGvHD and in-
house experience (47, 48). Systemic oral corticosteroid treatment was not 
included in the treatment schedule, but was prescribed by the hematologist in 
close cooperation with the gynecologist.  
 
3.6 Sex-related personal distress and depression 
The Female Sexual Distress Scale (FSDS), and the Beck Depression Inventory 
(BDI) were also completed at each study visit (49-51). A score of ≥15 in the 
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FSDS was used as the cut-off for sex-related personal distress. In the BDI, 
scores for depression ≥14 are ranked as mild, ≥20 as moderate, and ≥29 as 
severe. With the consent of the woman the gynecologist discussed the questions 
and answers in the FSDS and the BDI with the woman. Sexual advice and 
information were given as per the individual woman´s request. The gynecologist 
ESK is also a clinical sexologist. 
  
3.7 Genital biopsies for histopathological examination 
In Study I, genital mucosal biopsies were obtained from 38 women from areas 
macroscopically suspicious for cGvHD (n=25), and from mucosa with no 
clinical cGvHD (n=31). Only the first biopsy taken from either vulva or vagina 
was used for the analysis of the relationship between clinical signs and 
histopathological features. Thus systemically skewed results due to multiple 
biopsies were avoided. Two pathologists examined each serial section. They 
used histopathological criteria  to diagnose cGvHD (52). Assessments of 
findings of each biopsy were standardized into 1 of 4 categories: no cGvHD, 
possible cGvHD, consistent with cGvHD, or cGvHD. See Fig.1 in Paper I.  
 
3.8 Laboratory methods 
Comprehensive laboratory screening was performed in Study II. Serum levels of 
total and free testosterone (T) and DHEAS, were assessed at an accredited 
laboratory specialized on very low levels of androgens. HRT and oral 
contraceptives (OCP) were interrupted 24 h before blood sampling in all groups. 
The analyzing technics are described in detail in Paper II.  
 
3.9 Statistics 
For dichotomous variables either Fisher’s exact test or Pearson’s chi-squared 
test were used in all studies and p-values < 0.05 were considered statistically 
significant. In Paper I and II for continuous variables Wilcoxon’s rank-sum test 
was applied and nonparametric trend test was used to analyze ordered 
categorical variables (53). The simple linear regression model was used to 
analyze means in Paper II and the regression coefficients were compared by 
means of normal approximation. This was used to analyze the association 
between age and DEAS and free T respectively. Mann-Whitney-U-test was used 
in Paper III and IV to compare continuous variables. 
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4 RESULTS 
4.1 Paper I. Genital chronic Graft-versus-Host Disease in 
females: a cross-sectional study. 
The hypotheses of our first study was 
a. that genital cGvHD might be underdiagnosed in women after alloSCT 
b. that genital cGvHD implies suffering and discomfort 
c. that genital cGvHD has characteristic histopathological features. 
 
4.1.1 Prevalence of genital chronic GvHD 
Forty-two women were included in this cross-sectional study. The prevalence of 
genital cGvHD was 52% (n=22), to be compared with oral (43%) and ocular 
(40%) cGvHD. Seventeen of 42 (40%) women had fibrotic constrictions in the 
vagina (n=16), vulva (n=4) or in both locations (n=3). Six women had surgical 
treatment for vaginal stenoses before entering the study. Three of these women 
underwent surgery without cGvHD diagnosis and were prescribed only local 
estrogen as follow-up treatment. All 3 relapsed promptly.  
Before inclusion, 10 women had been diagnosed with cGvHD by one of the 
gynecologists (ESK). In 12 cases genital cGvHD was unrecognized by the 
woman and found to be underdiagnosed. Clinical scoring was dominated by 
score 3 (n=12). The remaining women scored 2 (n=2), 1 (n=6) and 0 (n=2). The 
last two had no symptoms but showed diagnostic signs of genital cGvHD. The 
rate of severe global scoring was 15 of 42, mainly based on a genital clinical 
score of 3. 
 
 4.1.1.1 Symptoms  
Suffering and discomfort associated with genital cGvHD was self-reported as 
described in 3.5. Compared to women without genital cGvHD, dryness, 
smarting pain, pain-when-touched, and dyspareunia was significantly more 
common in women with genital cGvHD (p<0.05).  
 
4.1.2 Depression and sex-related personal distress  
Data on depression and sex-related personal distress were not published in Paper 
I. There was no statistical difference between women with or without genital 
cGvHD as per the BDI and FSDS instruments. To the BDI question No 21 about 
sexual interest, 17 of 37 women (46%) answered the alternatives “I am much 
less interested in sex now than earlier” or “I have completely lost my interest in 
sex.” 
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4.1.3 Histopathological examination 
In women with clinical cGvHD at the location of the biopsy (n=14) the 
histopathological grades were evenly distributed from 0 to 3, i.e. “normal” to 
“confirmed” cGvHD. Biopsies were more often confirmative in mucosa without 
clinical cGvHD, with 17 of 24 biopsies graded 0-1 (normal - possible cGvHD). 
In 4 women with clinical vaginal cGvHD, biopsies from clinically normal vulvar 
mucosa showed grade 2-3, consistent with cGvHD. Three other biopsies were 
graded 2-3 (consistent with cGvHD) although they were obtained from clinically 
normal vulvar mucosa (the vagina was clinically normal). Taken together, we 
found no relationship between clinical findings and histopathology.  
 
4.1.4 Effects of estrogen treatment  
At their first visit, all women were in menopause, 11 natural and 31 premature 
as a consequence of the conditioning treatment. Twenty-nine women were on 
hormonal replacement therapy: 21 of these women had oral estrogen/gestagen, 
and 8 women were on local estrogen therapy. Thirteen of the 29 patients on 
HRT, and all the women not receiving hormonal therapy (n=13), needed 
complementary local estrogen because of mucosal atrophy.  
At the second visit, genital symptoms and signs typically associated with 
estrogen deficiency – dryness, pain-when-touched, smarting pain – were 
alleviated in approximately one third of the women. The number of women 
reporting dyspareunia was reduced from 52% to 32% among those having 
coitus. Seven women with clinical signs of estrogen deficiency had no 
symptoms at their first visit, but nevertheless reported more well-being in their 
genitals when local estrogen treatment was used.  
The main differences in signs at the second visit were the decrease of the 
thinness, and an increase of normal texture of the mucous membranes. However, 
estrogen treatment did not affect the diagnostic or distinctive signs of genital 
cGvHD, including reticular white lines and teleangiectatic areas, vaginal sore 
strings, synechiae or stenosis. See table 4. 
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Table 4. Genital signs before and after local estrogen therapy. In Study I, all 
participating women, n=42, underwent gynecologic examination,  
were prescribed complementary local estrogen therapy at their first study visit.  
Diagnosis of genital cGvHD was made at least 6 weeks later at a second visit. 
 
 Genital status 
Signs Before local 
estrogens 
After local 
estrogens 
Vulvar signs   
Normal 16 20 
Red spots 18 14 
White spots 9 8 
Reticular white lines 6 7 
Teleangiectatic areas 0 1 
Vulvar mucous membrane   
Normal 6 14 
Thin 35 27 
Dry 7 6 
Reddened 4 3 
Edematous 1 2 
Vulvar wounds   
Fissures 5 4 
Vaginal signs   
Normal 23 26 
Red spots 13 10 
White spots 3 3 
Teleangiectatic areas 2 4 
Reticular white lines 2 2 
Vaginal mucous membrane   
Normal 19 30 
Thin 23 11 
Dry 3 1 
Edematous 1 1 
Thick and non-elastic 3 1 
Reddened 2 1 
Synekiae/ stenosis   
No stenosis/synekia 22 22 
Synekia vulvae 6 6 
Synekia vaginae 13¹ 12 
Sore vaginal string 5 5 
Partial stenosis of the vagina 5 5 
Total stenosis of the vagina 4 4 
23 
                                                     
¹One small synechia was broken by the gynecological examination at the first visit and was completely 
disappeared after estrogen treatment. 
One woman could have more than one sign. 
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4.1.5 Corticosteroids and genital cGvHD  
The presence of genital cGvHD was associated with systemic corticosteroid 
treatment of extra-genital cGvHD (p =0.001), older age (p= 0.07), and transplant 
from a sibling donor (p=0.002).  
Thirteen of the 22 women with genital cGvHD were on systemic corticosteroid 
therapy with extragenital cGvHD as the indication in all cases. Five women had 
only genital cGvHD, 3 of them with clinical score 3. The rate of genital cGvHD 
was similar among the women with follow-up on both sides of the median time 
after transplant. 
 
4.1.6 Summary 
The assessments in this cross-sectional study revealed that symptoms and signs 
of genital cGvHD were a common scenario, and often not correctly diagnosed or 
treated. The findings indicated a high prevalence of genital cGvHD similar to 
that of ocular and oral cGvHD. Genital cGvHD was associated with serious 
consequences for sexual life because of pain and may be present without any 
other cGvHD and, actually, even without genital symptoms if the women did not 
have intercourse. We found no relationship between clinical findings and 
histopathology. 
 
 
4.2 Paper II. Androgens in women after allogeneic 
hematopoietic cell transplantation: impact of chronic GvHD 
and glucocorticoid therapy. 
  
4.2.1 Background 
Chronic GvHD and its effects on genital mucosa may cause sexual dysfunction, 
and premature ovarian failure affects all women after alloSCT. We did the clinical 
observation that sexual dysfunction prevailed also after substitution with local and 
systemic estrogens. Testosterone is positively associated with sexual function 
(54), and data on post-transplant levels are scarce. Dehydroepiandrosterone 
sulfate has after conversion multiple effects on physical well-being, including 
sexuality. However, data on androgen levels in female patients after alloSCT are 
limited (37, 55). 
In this study we assessed serum T, free T and DHEAS in allografted women 
with/without cGvHD, and with/without treatment with GC.  
 
4.2.2 Hypotheses 
• Women after alloSCT have lower androgens than age-matched healthy women. 
• Women after alloSCT have lower androgens compared to women after autoSCT 
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• Glucocorticoid treatment is associated with low androgens 
• Chronic GvHD per se increases the risk of subnormal level of T and DHEAS.  
 
4.2.3 Patients. Controls. 
For this study 205 women (4 groups) were included.  
1. Allo-SCT, n=65, age 51 (21-74) yrs; 55 (3–194) months post alloSCT 
• Ongoing cGvHD (n=33) 
i. with prednisolone (n=23) 
ii. without prednisolone (n=10)  
• No cGvHD (n=32), no corticoid steroids 
2. Auto SCT, n=20; age 55 (34-65).  
3. Glucocorticoid group, n=26; age 62 (23-82). Prednisolone for benign 
disease  
4. Controls, healthy women, n=94; age 49 (26-74).  
 
4.2.4 Methods 
All samples for hormone determination were assessed at accredited laboratories. 
Statistics:  
• Androgen levels were compared between the 4 main groups.  
• In a second step, the effect of cGvHD and ongoing GC therapy was 
studied by dividing the alloSCT group into subgroups, comparing them 
internally and with the other groups. 
 
4.2.5 Results 
• AlloSCT group. All androgens analyzed – T, free T and DHEAS – were 
lower compared to control and autoSCT groups (P<0.05 for all).  
o AlloSCT/no-GvHD group: Free T similar, DHEAS lower than 
controls. 
o AlloSCT/GvHD group: Significantly lower androgen levels than 
alloSCT/no GvHD group; free T (3.2 vs 7.2 pmol/L, p=0.0001), 
DHEAS (0.5 vs 1.7 μmol/L, p<0.0001).  
 AlloSCT/cGvHD with GC group (n=23). Free T & DHEAS 
lower than in any other group.  
 AlloSCT/cGvHD/ without GC group (n=10): Both free T and 
DHEAS were lower than controls: 4.9 vs 8.6 pmol/L, p=0.004, 
and 1.5 vs 2.5 μmol/L, p=0.0004, respectively. But not 
significantly lower than the no-GvHD group: free T; p=0.068, 
DHEAS p=0.18. 
• AutoHCT group: T and free T were higher, but DHEAS similar, to 
controls 
• Glucocorticoid group: T, free T and DHEAS lower compared to control 
and autoSCT groups (p<0.05 for all).   
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 4.2.6 Summary 
• AlloSCT but not autoSCT is associated with low androgens. 
• Glucocorticoid treatment, is associated with low androgens.  
• The lowest levels of androgens were seen in allografted women with 
cGvHD and GC treatment.  
• Women after alloSCT with no cGvHD had similar free T, but lower 
DHEAS compared to controls.  
• Compared to the no-cGvHD group, women with cGvHD but no GC 
treatment (n=10), had a tendency to lower T (p=0.068), but similar 
DHEAS. 
 
4.3 Paper III. A prospective study of female genital chronic 
Graft-versus-Host Disease symptoms, signs, diagnosis, and 
treatment. 
The hypothesis of this study of allografted women (n=41) was that regular 
gynecological surveillance, in close contact with the hematologist, might 
provide early diagnosis and intervention to reduce the problems associated with 
genital cGvHD and also decrease the risk of serious sequel.   
Other questions that we sought to answer: 
• What are the debut signs and symptoms of genital cGvHD?  
• What is the relationship in time between genital and extra-genital cGvHD?  
 
4.3.1 Rationale  
In our first study (Paper I), we could see from medical reports that 8 of the 42 
women had developed total vaginal stenosis in the period up to 36 months after 
alloSCT. Consequently, this study included regular gynecological examination 
with short intervals during the first year and longer intervals during the next 2 
years and prompt local treatment at first sign of cGvHD. The aim was to try and 
reduce the incidence of severe genital cGvHD. The plan included close 
communication between gynecologist and hematologist.  
 
4.3.2 Diagnosis and treatment 
Genital cGvHD was diagnosed in 27 (66%) women with an incidence of 56% at 
12 months and 66% at 36 months. Median time to first sign was 6 (1-30) months 
Extra-genital cGvHD was observed in 21 women with genital cGvHD and 10 
without genital cGvHD. Four women had their first sign of genital cGvHD later 
than 21 months. Thirteen women started local immunosuppressive treatment of 
genital cGvHD median 9 (1-31) months after alloSCT. Another 14 women did 
not get local immunosuppressive treatment because of pathological Pap smear, 
infection, relapse, fluctuation or disappearance of signs, or no symptoms.  
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4.3.3 Signs, symptoms, treatment  
At first sign of genital cGvHD itching, dryness, smarting pain, dyspareunia and 
discharge were common symptoms. Notably, 30% of the women were 
symptom-free. The most common signs at first diagnosis were reticular white 
lines and synechiae, red-and-white spots and thin mucous membranes. More 
advanced fibrosis or partial stenosis were later findings. Despite treatment, we 
observed that signs and symptoms became chronic. 
 
4.3.4 Five women with 7 circumferential fibrous vaginal bandings or 
partial vaginal stenoses and 2 total stenoses. 
Five women had partial stenosis or circumferential fibrous vaginal banding. See 
Figure 1 concerning localization, thickness and duration of the stenoses. All 5 
were prescribed local immunosuppressive treatment (see Treatment schedule, 
Table 2, Paper III).  
Patient No. 1 no GC treatment. Signs of synechiae vaginae, and signs of cGvHD 
in mouth and eyes, occurred at 9 months during tapering of ciclosporin. Local 
immunosuppressive treatment started at 9 months. At 18 months she had sore 
vaginal strings and a circumferential fibrous vaginal banding, however still with 
few symptoms. The banding disappeared, but the sore vaginal strings continued 
and the synechiae remained at 36 months. The local immunosuppressive 
treatment continued with successive tapering and at 36 months she was on 
maintenance treatment.  
No. 2, her genital cGvHD started with reticular white lines and fissures in the 
vulva and erythema in the vagina at 1 month after alloSCT, from 3 months she 
had active cGvHD in mouth and eyes. Full local genital immunosuppressive 
treatment started at 1 month, was reduced to maintenance treatment at 6 months. 
At 12 months full treatment was started again because of partial stenosis at 12-
34 months, synechiae vaginae at 17-36 months and sore vaginal string at 19-27 
months. (Like the others with active genital cGvHD she was seen also outside 
the protocol for clinical reasons). See figure 1. At 36 months she had red-and-
white spots, was reddened in the vulva, had synechiae vaginae and was on 
maintenance local immunosuppressive treatment. Parallel with this the woman 
was treated with GC 25 mg when ciklosporin had been withdrawn at 16 months, 
successively tapered to 7.5 mg at 36 months. 
No. 3 never had any extra-genital cGvHD but got her first signs of genital 
cGvHD at 9 months, sore vaginal string and synechiae vaginae. Daily local 
immunosuppressive treatment was prescribed. Two weeks later there was a 
partial stenosis. The woman had only used the treatment once a week. On 
adequate local treatment she got better and then worse again. At 21 months she 
had circumferential fibrous vaginal banding on two different levels in the 
vagina, as shown in figure 1. The cooperative hematologist prescribed GC  
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20 mg/day which 2 months later was tapered to 7.5 mg every other day. At 36 
months the dosage was 2.5 mg every other day. The local immunosuppressive 
treatment had continued. The outer circumferential fibrous vaginal banding 
disappeared. The woman was seen at the clinic after the study. The inner partial 
stenosis became successively wider and when coitus started at 41 months post 
alloSCT there was no dyspareunia.  
The two total stenoses both had the form of a membrane covering the cervix. 
Woman No. 4 in Figure 1 started local immunosuppressive treatment of the 
vulva because of distinctive signs and extra-genital cGvHD at 4 months, tapered 
at 6. Because of extra-genital cGvHD with global score 3 systemic GC were 
prescribed 50 mg/day at 6 months, at 9 months 15 mg and one month later 10 
mg/day. At 9 months post alloSCT the woman re-started scheduled local 
treatment of the vagina because of sore vaginal string and synechiae vaginae et 
vulvae. At 12 months the systemic GC were 12,5 mg/day. The genital cGvHD 
signs included now also partial and complete vaginal stenosis, and fissures and 
reticular white lines in the vulva. She had extra-genital cGvHD in the mouth, 
eyes and skin. At 13 months post alloSCT she relapsed and died one month 
later. 
The genital cGvHD of woman No. 5 started slowly with reticular white lines in 
the vulva at 12 months with no symptoms. Local estrogen treatment was used. 
GC treatment was 5 mg/day. At 18 months the genital signs were vaginal sore 
string, synechiae and partial stenosis, vulvar red-and-white spots and reticular 
white lines. Local immunosuppressive treatment of the vulva and vagina was 
started according to schedule. The synechia vaginae disappeared, but sore 
vaginal strings continued and another circumferential fibrous vaginal banding 
developed. At 36 months she had vaginal strings and fibrous vaginal banding on 
two different levels as seen in Figure 1 together with the membrane covering the 
cervix. She had extra-genital cGvHD in the eyes with clinical score 1 and 
systemic GC 5 mg/day.  
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4.3.5. Depression and sex-related personal distress  
The presence of genital cGvHD was associated with higher BDI at 6 and 24 
months after alloSCT (p=0.011 and p=0.024 respectively). FSDS did not differ 
significantly between the groups with or without genital cGvHD. In the total 
study cohort, maximum FSDS (≥15) was reported in 29% of the responders at 
24 months after alloSCT, compared with 18% before and 36 months after 
alloSCT. 
 
4.3.6 Summary 
The incidence of genital cGvHD is high and typically develops during the first 
year after alloSCT. Signs and symptoms fluctuate with or without local 
treatment, and the disease is likely to last for more than 36 months. Treatment 
intervention may halt progression to severe genital cGvHD. 
 
 
4.4 Paper IV. Long-term follow-up of genital chronic Graft-
versus-Host Disease in females after allogeneic stem cell 
transplantation.  
We hypothezised that signs and symptoms of genital and other cGvHD may 
alleviate over time.  
 
4.4.1. Study design  
This was a long-term, follow-up study on surviving women (n=38) from Study I. 
Median time since transplant was 14.5 (10-19.3) years, and 8.4 (5.8-12) years 
after inclusion in Study I. Each woman was evaluated by an ophthalmologist 
(KS), a gynecologist (ESK) and 1 of 2 hematologists (MB or YB), on the same 
day. Diagnosis and stage of cGvHD was based on the NIH 2014 guidelines. For 
the comparisons between Study I and IV, data from Study I were examined and 
recategorized as per NIH 2014.  
 
4.4.2 Results 
Twenty-five women (66%) had stopped using adequate local estrogen therapy 
prescribed as part of Study 1, and subsequently had symptoms from atrophic 
genital mucosa at the late follow-up.  
Ocular cGvHD was seen in 24 women, genital cGvHD in 22, and extra-genital 
(including eyes) in 25 (missing data, n=1). Concurrent genital and extra-genital 
cGvHD were identified in 16 women. See Table 5. Six women had only genital 
cGvHD, and 9 only extra-genital cGvHD. Six women (16%) had no cGvHD.  
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Table 5. Genital and non-genital cGvHD in all surviving women from Study I 
(original study) and in Study IV. 
 
 
Original study 
(n=38) 
Follow-up study 
(n=38) 
P value 
Genital cGvHD (Yes/No) 19/19 22/16 0.646 
Non-genital cGvHD (Yes/No) 22/16  ¹25/12 0.476 
Chronic GvHD (Yes/No) 28/10 31/6 0.399 
Oral glucocorticoids (Yes/No) 13/25 11/27 0.805 
GvHD global score (NIH 2014)    
None 10 6  
Mild 7 6  
Moderate 5 4  
Severe 16 21  
None/Mild vs Moderate/Severe 17/21 ¹12/25 0.345 
1 One patient, data missing on extra-genital cGvHD in follow-up study. 
cGvHD, chronic Graft-versus-Host Disease, NIH, the National Institutes of Health 
Three women with genital cGvHD in Study I had no genital cGvHD at follow-
up; but two of them had extragenital cGvHD in Study IV (missing data, n=1).  
Six women with no genital cGvHD in Study I, now had signs of genital cGvHD. 
Two of these 6 women had labial fusions and one of these women had also a 
stenosis of the cervix. Apparently, their genital cGvHD had developed between 
the two studies i.e. between 5-12 years and 9-17 years after alloSCT, 
respectively. Compared with findings in Study I, both these women had more 
extra-genital cGvHD in the follow-up study: in 1 woman mouth, eyes, and joints 
were affected; the second woman showed involvement of eyes, gastro-intestinal 
tract, skin, mouth, and joints.  
All cervical smears were normal. However, HPV types associated with 
development of cervical cancer were found in 3 women. 
 
4.4.3 Treatment 
Local treatment was not part of the study protocol. Local immunosuppressive 
ointments, clobetasol (0.05%) and tacrolimus (0.1-0.03%) were prescribed 
following a structured treatment schedule, modified according to signs and 
symptoms. See Table 2 in Paper III.  
 
4.4.4 Depression and sex-related personal distress  
Using the BDI and FSDS instruments, there were no statistical differences 
between women with or without genital cGvHD, although a comparison of the 
original and follow-up studies indicated a tendency to improvement with respect 
to both BDI and FSDS. However, dyspareunia score 2-4 (sometimes to always) 
was self-reported by 15 of 27 (56%) of women with genital cGvHD having or 
tried coitus. 
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4.4.5 Summary 
Women’s genital mucosa is a major target for cGvHD. Structural signs such as 
vaginal stenosis rarely disappear over time. Genital cGvHD may debut many 
years after transplant. The use of local estrogen therapy continues to be important. 
Obviously, cGvHD rarely heals even after a very long time. However, depressive 
symptoms seem to decline over time.  
Looking at each woman´s global cGvHD in the original and follow-up study 
(Table 5, Paper IV), we observed movements between global severity scores in 
many patients. Movements were noted in both directions, and reasonably reflect 
the clinical experience that signs – and also symptoms – of cGvHD in affected 
tissues or organs may differ in severity over time.  
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5 DISCUSSION 
5.1 Introduction  
Study I describes the prevalence of female genital cGvHD, 52%, median 80 
(13-148) months after alloSCT. 
Study II accounts for androgen levels in women after alloSCT with/without 
cGvHD, and on glucocorticoids. There are 3 control groups: i) women after 
autoSCT; ii) women on glucocorticoid treatment for non-malignant disease; 
iii) age-matched healthy women. 
Study III is a prospective population-based study of genital cGvHD with 
cumulative incidence 56% at 12 months and 66% at 36 months. 
Study IV is a long-term follow-up study of surviving women from Study I. 
Median follow-up was 174 (120-232) months after alloSCT with prevalence 
cGvHD the same as in Study I. 
See Table 2, page 13, for summary of the studies. 
 
5.2 Diagnosing cGvHD 
The diagnoses of genital and extra-genital cGvHD were made according to NIH 
2005 in Study I, II and III, and to NIH 2014 in Study IV. In Study III most 
(85%) genital cGvHD debuted during the 1st year after alloSCT; later debuts 
occurred up to 30 months. Even later debuts were seen in Study IV, 5-17 years 
after transplant. Earlier investigators have reported lower figures; Zantomio 
found 35% at 1 year, 49% at 2 years (20). Our higher figures may be due to a 
strict application of the NIH criteria. NIH 2014 stressed all fibrotic signs both in 
the vagina, as NIH 2005 did, and the vulva with labial fusion, and clitoral hood 
agglutination as examples. Vulvar erythema and lichen sclerosus were also 
considered as diagnostic signs.  
The diagnosis could be difficult, even if the two gynecologists always tried to 
examine the woman together. Reticular white lines could be vague, both in the 
genitals and in the mouth. Erythema might mimic local infection. The 
assessments of extra-genital cGvHD in Study I and III were obtained from 
medical records, with some risk of non-uniform cGvHD grading. Sometimes 
time solved the problem with appearance of more distinct diagnostic signs, or 
disappearance of the vague suspected signs. We assumed that red and white 
spots, described in Study III and IV are identical to the “local mucosal paleness” 
described by Hirsch (22). They give the mucous membrane a very characteristic 
mottled appearance. Actually, in Study IV all women with red and white spots 
also had other distinctive and diagnostic signs of genital cGvHD. 
In Study IV, two women without genital cGvHD in Study I had developed labial 
fusions, a fibrotic sign of genital cGvHD, and more extra-genital cGvHD. Their 
genital cGvHD had developed between the two studies i.e. between 5-12 years 
and 9-17 years after alloSCT. Thus, very late debuts of genital cGvHD. 
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As is pointed out by Jagasia, there is a want of distinction between active 
disease and a fixed deficit like a fibrotic stenosis from prior tissue damage (45). 
Four women in Study IV illustrate this. Photos from Study I of 4 women without 
the diagnosis genital cGvHD were compared with the findings of their labial 
fusions in Study IV. We found that they also had labial fusion in the first study 
without any symptoms. For 2 women the photos showed the same labial fusions 
in both Studies I and IV. In the follow-up study one woman had no symptoms 
and the other had smarting pain, itching and dryness, and often fissures. The 
labial fusion in the first woman might be an end stage of passed genital cGvHD, 
and not an active disease (45). The genital cGvHD in the second women seems 
to be an active disease according to her fissures and symptoms. 
The photos of the other 2 women with labial fusion in the original study 
revealed that a development to more severe labial fusions had occurred until the 
follow-up study. Both had developed bilateral labial fusion along the whole lips 
and one had also clitoral hood agglutination. Neither of them had extra-genital 
cGvHD. Both needed local estrogen. Their genital cGvHD might be a more 
progressive type of genital cGvHD.  
Stratton concluded that genital cGvHD always starts in the vulva (21). However, 
in our Study III the first sign of genital cGvHD was in the vulva in 18 women, in 
the vagina in 4, and in both the vulva and the vagina in 5. Throughout the study 
15 of 27 women had cGvHD in both the vagina and the vulva. One woman had 
only vaginal cGvHD during the study, 11 only vulvar cGvHD. Preemptive 
treatment of the vagina, simultaneously with treatment of vulvar genital cGvHD, 
did not hinder the development of vaginal cGvHD. 
 
5.3 Effects of estrogen 
Estrogen did not affect the signs of genital cGvHD in the mucous membranes in 
Study I (see Table 4). In Study III, treatment of genital cGvHD with clinical 
score 0-1 started with local estrogen in 9 women. During estrogen treatment, 6 
women with diagnostic or distinctive signs of cGvHD in the vulva and/or the 
vagina cleared all signs of cGvHD. Reversible signs included teleangiectatic 
areas, reticular white lines, synechiae, reddened mucosa, fissures, red-and-white 
spots, and sore vaginal string. There was no corresponding effect of estrogen in 
Study I. This difference in response to estrogen treatment was at least partially 
due to the differences in follow-up time since transplant between the two 
groups. In the prospective Study III, the transplant was recent and the signs of 
genital cGvHD even more recent, whereas in Study I the women had long 
duration since transplant, and the signs were probably older than in Study III. 
The fresher signs in Study III may have been easier to affect. However, 
immunosuppressive therapy is more effective with concomitant estrogen 
treatment (21). Time is another factor influencing what is happening. The 
genital cGvHD in itself is a pendulating disease as illustrated by the fact that of 
the 6 women mentioned above one woman had had vulvar cGvHD 21 and 24 
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months before that “only-estrogen-treated” period, and in another woman the 
diagnosis of vulvar cGvHD reappeared 9 months after the described period. See 
table 5 in Paper IV. 
In Study IV the women were seen only once. Sixty-six percent had stopped local 
estrogen therapy and had developed atrophic mucous membranes. Their self-
reported genital symptoms were a mix of atrophic symptoms and symptoms 
from genital cGvHD. Therefore genital symptoms could not be ascribed any of 
the causes atrophia or genital cGvHD, e.g. the dyspareunia described in 4.4.4. 
 
5.4 Local immunosuppressive treatment 
We have chosen a treatment with both the ointments clobetasol 
(glucocorticosteroid group IV) and tacrolimus (calcineurin inhibitor) with the 
intention of achieving a maintenance treatment with tacrolimus together with 
local estrogen. The intention was to avoid clobetasol once the mucous 
membranes had improved and perhaps become more sensitive to the attenuating 
effect of the corticosteroid. Temporary burning sensations were reported at start 
of treatment by 9 women in Study III. However, none of them had to stop using 
ointment because of that. We did not prescribe immunosuppressive ointment 
more than once a day. Other authors suggest start twice a day on clobetasol (29). 
A treatment with both ointments, i.e. clobetasol and tacrolimus, once every day 
would also be an alternative aggressive local treatment, hopefully reducing the 
need for systemic corticosteroid treatment or surgery. When using local 
tacrolimus, analyses of whole blood levels should be performed to avoid 
nephrotoxic levels. Only once we had to reduce the genital use of tacrolimus 
because of nephrotoxic risk. We have seen the fibrotic process respond to 
treatment as long as the woman continued to treat. As soon as the treatment is 
tapered, the fibrotic process starts again, see e.g. patient No 3 in 4.3.4.  
If the local treatment fails, systemic corticoids are indicated after agreement 
with the hematologist.  
 
5.5 Other treatments for genital cGvHD 
Fibrotic vaginal cGvHD was treated with a dilator, if coitus without dyspareunia 
was not possible, or wished for. To avoid the development of vaginismus the 
woman was advised to use the dilator with an adequate amount of lubricant, 
inserting the dilator very slowly to avoid pain, and waiting for muscular 
contractions to relax before continuing insertion.  
Surgery was not performed in any of the studies, only before Study I and 
between Studies I and IV. Surgically opening of vaginal stenoses with only 
estrogen treatment afterwards, lead to prompt relapses. Obviously, surgery is a 
temporary solution; it does not cure genital cGvHD. In our studies 5 women 
have been surgically treated for their stenoses 8 times in spite of adequate 
treatment after. As soon as the woman has stopped her local treatment, the 
fibrosis relapses again. 
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There is a necessity of immuno-suppressive treatment after surgery. 
 
5.6 Treatment risks 
Local immunosuppressive treatment brings risks. HPV may reactivate and 
stimulate development of squamous cell atypias into malignant cells(32). That is 
one reason for starting the treatment of genital cGvHD with local estrogen only, 
or waiting and seeing. We have seen the signs of genital cGvHD disappear 
without further treatment, as described above, or remain at the same level for a 
long time without deteriorating (Study III). But we have also seen fast 
impairment as described among the women with partial stenosis in Study III. 
All our women were attending the Swedish cervical cancer screening program 
before and during the studies, and were investigated, when atypical cells were 
found, and treated when the histopathological assessment showed pathology. 
During the Studies I, III and IV no genital malignancy was found. Fourteen 
women in Study IV, and 15 in Study III had had atypical cells; of those 22 
women, 11 from each group, were also diagnosed with genital cGvHD. Between 
Study I and IV, 5 women had been treated for 6 different malignancies, 3 in the 
oral cavity, 2 basaliom and 1 colon cancer; a reminder of the increased risk for 
malignancies after alloSCT (34). 
 
5.7 Depression and sex-related personal distress 
We used the completed BDI and FSDS questionnaires at each study visit to 
discuss the answers given by the woman in relation to depression and sexual 
function in the Studies I, III and IV. This facilitated the giving of sexual advice 
to the women, when wanted, and the diagnosing of depression for referral and 
treatment.  
Our approach thus included a frequent psychosexual intervention that might 
have influenced the results, at least in the prospective Study III. The women in 
our studies showed considerably less sexual distress (14-29%) than was found in 
other studies, where 66-80% of female survivors of alloSCT were affected by 
sexual distress in addition to dyspareunia, problems with sexual dysfunction, 
libido, sexual activity and satisfaction (35, 56, 57). According to Humphreys 
assessing and addressing depression at pre-transplant stage may reduce sexual 
dysfunction in long-term survivors. The depression frequency decreased from 
28% before transplant to 14% at 36 months. Mosher et al. found that 15% of the 
sample of alloSCT men and women reported moderate to severe depressive 
symptoms, and these symptoms were higher among allogeneic transplant 
recipients and those with lower functional status (58). Between the original 
Study I and the follow-up Study IV moderate to severe depression was lowered 
from 18% to 5%. The personal sexual distress changed from 55% to 37%. 
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5.8 Clinical and global scoring 
The clinical scoring according to NIH 2014, applied in Study IV, is more 
adequate and easier to implement than NIH 2005. However, the scoring of 3 for 
all levels of fibrosis implies that many women by definition will have a severe 
global score even although they have minor signs of fibrosis. Symptom-free 
labial fusion of the vulva without any extra-genital cGvHD will reasonably not 
affect survival.  
 
5.9 Fertility 
Fertility and pregnancies were not part of the protocol in any of our studies. 
Salooja et al. 2001 reported 312 pregnancies in 232 patients or partners of 
patients among 19412 alloSCT and 17950 autoSCT patients, i.e. 0.6% (59). 
After our studies 3 women have become pregnant, 2 spontaneously and 1 after 
assisted fertilization. The possibilities to help couples with assisted fertilization 
is increasing to-day. However, the infertility that follows alloSCT is a problem 
and a life-long sorrow for younger allografted women. 
 
5.10 Fibrotic genital cGvHD 
The finding that 2 women with vaginal stenosis, 1 total and 1 partial, in the 
follow-up Study IV did not have other cGvHD, implies that the genital fibrotic 
process may not be reversible. In Study III however, synechiae were signs 
disappearing on only estrogen treatment, and circumferential fibrous vaginal 
bandings disappeared on local immunosuppressive treatment (see Figure 1). It 
seems that there are different kinds of fibrotic genital cGvHD. A chronic variant 
that is active as soon as treatment tapers, and relapses without tendencies to 
reverse spontaneously. Another variant of fibrotic genital cGvHD is partial 
stenosis, disappearing on treatment without relapse during observational time. 
And then there is the very slow developing fibrosis of the vulva in the form of 
labial fusions. We have not studied if this process occurs in parallel with 
inflammatory periods of sore mucous membranes with lichen planus-like signs. 
Many women report that those periods often are connected with viral infections 
e.g. in the form of upper respiratory infections. 
 
5.11 Androgens and cGvHD 
Hovi found that low DHEAS were a consistent finding during GC therapy for 
cGvHD, and ask if that might be due to adrenal insufficiency and/or 
dysfunctional ovaries (39). In our Study II, androgen-producing ovarian cells 
seemed to be resistant to high-dose chemotherapy, but sensitive to GC, and 
possibly also to cGvHD. In non-transplanted women with GC therapy, 
androgens were significantly lower than in controls. This suggests that the GC-
effect on adrenals and a secondary adrenal insufficiency is the cause of the 
lowered androgens seen in these non-transplanted women. However, we do not 
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know if low androgens in women with cGvHD and on GC treatment, also is 
dependent on secondary adrenal insufficiency, or the cGvHD effect on the 
adrenals, or both. AlloSCT, irrespective of cGvHD and GC therapy, was 
associated with low DHEAS levels. This might indicate an effect from the 
alloSCT in itself on both ovaries and adrenals. 
 
5.12 Summary 
To our knowledge Study I is the first to try to establish a population-based 
prevalence of female genital cGvHD, while Study III is the first population-
based prospective study of genital cGvHD. In Study IV a long-term follow-up 
of surviving women from Study I, median 8.4 years after the original study, is 
described. Study II is a contribution to a field not yet much described, androgen 
levels in women after alloSCT.   
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6 CONCLUSIONS 
Chronic cGvHD is the major cause of morbidity after alloSCT, and contributes 
to NRM. Female genital mucosa is a major target for cGvHD.  
 
Study I. We observed that the prevalence of genital cGvHD in our cross-
sectional, population-based study was similar or higher than in previous reports.  
Study IV. This was a long-term follow-up of surviving women from Study I. 
The time lag between the two examinations was median 8.4 (5.8-12) years. The 
main finding was that prevalence and severity of chronic GvHD was almost 
identical to findings in Study I. One third of the women was still on systemic 
corticosteroids. Two women had a very late debut of genital cGvHD.  
Study III. In this prospective study, allografted women were regularly 
examined and treated for 3 years. Cumulative incidence of genital cGvHD was 
66%. However, in spite of local treatment, 5 women developed partial vaginal 
stenoses. But the incidence of total stenoses was seemingly lower compared 
with the findings in Study I (2 versus 8). The activity of the genital cGvHD was 
fluctuating with periods of more or less signs and symptoms. HRT should be 
prescribed to women with premature menopause. Local estrogen treatment do 
relieve symptoms and facilitate local immunosuppressive treatment of genital 
cGvHD.  
Study II. Androgen levels were assessed in a cohort of allografted women, and 
in 3 control groups. The main finding was that women on GC treatment had low 
androgens, with an additive effect of cGvHD. 
 
We conclude that genital cGvHD after alloSCT principally debuts the first year 
after transplant, and is a common and unresolved constant clinical problem 
associated with impaired sexual life, and inconvenience in terms of necessary 
local treatment increasing the risk for genital malignancy. The conclusion is the 
necessity of continuous contact with a dedicated gynecologist. 
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7 FUTURE PERSPECTIVES 
Reducing frequency and severity of genital cGvHD is a major challenge for the 
future. Ways to pursue that aim may include:  
 
1) A more frequent use of bone marrow instead of peripheral blood stem cells. 
 
2) Improved pre-transplant prophylaxis against cGvHD by e.g. anti-thymocyte
 globulin in doses adapted to a risk-benefit analysis.  
 
3) Close contacts between transplant physicians and experienced
 gynecologists. 
 
4) Systemic corticosteroids if aggressive genital cGvHD signs appear. 
 
5) Guidelines for the prevention and treatment of genital cGvHD, HPV
 vaccination and a schedule for more intensive local immunosuppressive
 therapy.  
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